Journal of Obesity & Metabolic Syndrome

Search

Best Practice

  • 1. Website
    • 1) The URL address of the official website is https://www.jomes.org.
    • 2) “Aims and Scope” statement: https://www.jomes.org/content/about/aimsnscope.html
      The aim of Journal of Obesity & Metabolic Syndrome is to improve the lives of those affected with and reduce the incidence of obesity-related metabolic syndrome by providing a better perception towards the prevention and treatment of obesity. It desires to contribute to the awareness and treatment of obesity through sharing of scientific information on the latest developments in obesity research among members of the Korean Society for the Study of Obesity, and also physicians and researchers worldwide. The journal publishes articles covering all aspects of obesity, particularly epidemiology, etiology and pathogenesis, treatment, and the prevention of obesity. It focuses on research on the basic and clinical aspects of obesity and obesity-related metabolic syndrome, as well as on the specific applications of biochemistry, physiology, genetics, and metabolic study to clinical practice. Nutritional, physical, psychological, and epidemiological aspects are also welcomed.
    • 3) Readership: It is primarily for endocrinologists and internists who seek tailored information that they can adopt in their research and practice. However, the journal’s readership can be expanded to other positions: researchers who have access to recent clinical medicine of obesity, obesity-related diseases research topics, and detailed research methods; clinicians in the field who have access to new information and recent obesity care developments for their patients; medical teachers who have access to and can adopt various medical education data; allied health professionals, including nurses, who have access to recent information concerning the care of obesity and obesity-related metabolic disorders; medical health students who can learn about the recent trends in the field and read about interesting cases; policymakers who can to reflect on the article results and apply them in nationwide healthcare policies for obesity and obesity-related metabolic disorders; and the public who will read about the advancements in obesity and obesity-related metabolic diseases, increasing their knowledge and inspiring confidence in the endocrinologists and internists’ devotion to obesity.
    • 4) Authorship criteria: https://www.jomes.org/content/authors/instructions-to-authors.html#body01 Authorship credit should be based on (1) substantial contributions to the conception and design of the study, acquisition of data, and/or analysis and interpretation of data; (2) participation in drafting the article or revising it critically for important intellectual content; (3) the provision of final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of it are investigated and resolved appropriately. Every author should meet all four conditions.

      The corresponding author takes primary responsibility for communication with the journal during manuscript submission, peer review, and publication. He or she typically ensures that all of the journal’s administrative requirements, such as providing details of authorship, ethics committee approval, clinical trial registration documentation, and gathering conflict of interest forms and statements, are properly completed, although these duties may be delegated to one or more coauthors. The corresponding author should be available throughout the submission and peer review process to respond to editorial queries in a timely way, and should be available after publication to respond to critiques of the work and cooperate with any requests from the journal for data or additional information should questions arise after publication. Authors are responsible for the whole content of each article.

      After the initial submission of a manuscript, any changes in authorship (adding author(s), deleting author(s), or rearranging the order of author(s)) must be explained in a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. JOMES does not correct authorship after acceptance for publication unless a mistake has been made by the editorial staff.
    • 5) pISSN: 2508-6235; eISSN: 2508-7576
  • 2. Name of journal
    The official title of the journal is “Journal of Obesity & Metabolic Syndrome” and the abbreviated title is “J Obes Metab Syndr"
  • 3. Peer review process
    https://www.jomes.org/content/authors/peer-review-policy.html
    Conformity of the submitted manuscript to the submission instructions is examined upon submission. If a manuscript does not conform to the instructions, the editorial board will ask the authors to resubmit the manuscript. Following the submission of a manuscript that conforms to the submission instructions, the editorial secretary reviews the topic of the manuscript and assigns it to an associate editor expert in the corresponding field. Based on the review results, the associate editor decides whether manuscripts will be able to proceed to the external review process or be rejected. The associate editor specializing in the field designates two reviewers for primary review of the manuscript. Review of a manuscript may be requested from reviewers specializing in the area in the list of the Korean Society for the Study of Obesity, reviewers recommended by the authors, or external experts in the area. We do not release reviewers’ identities to authors, as the policy of the journal is double-blind peer review. If changes are needed, it is recommended that authors should revise and amend the manuscripts. Authors of a revised manuscript must describe on a line-by-line basis how the manuscript was revised according to the instructions of the reviewers. Revisions must be received within two months from the date of the letter from the editorial board indicating that a revised manuscript would be considered for publication. If the revised manuscript is not returned within this period, the board will assume that the author has decided not to pursue publication. Based on the review results and revisions, the associate editor finally determines whether manuscripts are acceptable. If the review process is delayed for more than two weeks, the status of the manuscript review may be checked by text message, e-mail, or telephone call. Regarding acceptance policy, a manuscript that is “accepted” by both reviewers during the final review will be published. A decision of “rejection” is made if both reviewers reject the publication of the manuscript during the final review. If one of the reviewers rejects the manuscript during the primary review, the associate editor assigns a third reviewer to perform another primary review. If both of the initial reviewers or two of the three initial reviewers reject the manuscript during the first review, the associate editor transfers the final decision regarding acceptance of the manuscript to the editor-in-chief. The editor-in-chief will then make the final decision at the editorial board meeting. If two of the three reviewers accept and one of them rejects the manuscript during the final review, the associate editor will transfer the final decision regarding acceptance of the manuscript to the editor-in-chief. The editor-in-chief will then make the final decision at the editorial board meeting. Review of the statistical aspects of a manuscript is requested from a statistical review consultant and is reflected in the opinion of the reviewers. Review of an English language manuscript is requested from an English language review consultant during the primary review and is reflected in the final opinion. The editorial board may request the authors to oversee the final revision of English grammar in conjunction with an expert. At the editorial board meeting, which is held a month prior to the publication of each issue, the final list of articles to be published in the issue is determined from the articles currently accepted. Both accepted and rejected articles should be considered at the editorial board meeting for each issue. Articles receiving final approval for publication are assigned to an English language consultant for review.
  • 4. Ownership and management
    • 1) Ownership: https://www.kosso.or.kr/eng/
      This journal is owned by the publisher, Korean Society for the Study of Obesity.
    • 2) Management team: https://www.jomes.org/content/about/journal-managemen-team-and-credential.html
      • Journal Manager: Ji Seon Kim, Korean Society for the Study of Obesity, Korea
      • Manager of the Review Process:
        Changhee Jung, Associate Editor, Asan Medcial Center, Korea; Bo Kyung Koo, Associate Editor, Seoul National University Boramae Medical Center, Korea; Ga Eun Nam, Associate Editor, Korea University College of Medicine, Korea
      • Manuscript Editor: Young Ji Choi, InfoLumi, Korea; Ji Seon Kim, Korean Society for the Study of Obesity, Korea
      • Statistics Editor: Dae Jung Kim, Ajou University, Korea
      • Ethics Editor: Hyuk-Sang Kwon, The Catholic University of Korea, Korea
      • English Editor: Warren Lindeque, University of Johannesburg, South Africa; Jerry Nairns, Eworld Editing, USA
      • Layout Editor: Mi Hye Kim, Academya, Korea
      • Website and JATS XML File Producers: Eun Seok Chae, Inforang Co., Korea
  • 5. Governing body
    https://www.jomes.org/content/about/editorial_board.html
    The governing body is the journal’s editorial board.
  • 6. Editorial team / contact information
    • https://www.jomes.org/content/about/editorial_board.html
    • Editor-in-Chief

      You-Cheol Hwang, Kyung Hee University School of Medicine, Korea

    • Senior Editors

      Kyung Mook Choi, Korea University College of Medicine, Korea
      Soo Lim, Seoul National University College of Medicine, Korea
      Eun-Jung Rhee, Sungkyunkwan University School of Medicine, Korea

    • Associate Editors

      Changhee Jung, University of Ulsan College of Medicine, Korea
      Bo Kyung Koo, Seoul National University Boramae Medical Center, Korea
      Ga Eun Nam, Korea University College of Medicine, Korea

    • Executive Editor

      Eugene Han, Keimyung University School of Medicine, Korea

    • Editorial Board Member

      Arne Vernon Astrup, University of Copenhagen, Denmark
      Matthias Blüher, University of Leipzig, Germany
      Dongsheng Cai, Albert Einstein College of Medicine, USA
      Sung IL Choi, Kyung Hee University School of Medicine, Korea
      Nalinee Chongviriyaphan, Mahidol University, Thailand
      Sochung Chung, Konkuk University School of Medicine, Korea
      Andrea D. Coviello, Duke University, USA
      Nikhil Dhurandhar, Pennington Biomedical Research Center, USA
      Ele Ferrannini, CNR Institute of Clinical Physiology, Italy
      James G. Granneman, Wayne State University, USA
      Steven Heymsfield, Pennington Biomedical Research Center, USA
      Jason K. Kim, University of Massachusetts Medical School, USA
      Joon Young Kim, Syracuse University, USA
      Ki Woo Kim, Yonsei University College of Dentistry, Korea
      Tae Nyun Kim, Inje University Haeundae Paik Hospital, Korea
      Young-Bum Kim, Harvard Medical School, USA
      Alice Pik Shan Kong, The Chinese University of Hong Kong, Hong Kong
      Tony Lam, Toronto General Research Institute, Canada
      Jong Soon Lee, Soonchunhyang University, Korea
      Nader Lessan, Imperial College London Diabetes Centre, UAE
      Beverly Mühlhäusler, The University of Adelaide, Australia
      Martin Myers, University of Michigan Health System, USA
      Junghyun Noh, Inje University College of Medicine, Korea
      Patrick M. O'Neil, Medical University of South Carolina, USA
      Kyung Hee Park, Hallym University College of Medicine, Korea
      Masayuki Saito, Hokkaido University, Japan
      Ichiro Sakata, Saitama University, Japan
      Naveed Sattar, University of Glasgow, UK
      Jin Hee Shin, Duke University Medical Center, USA
      Yun-A Shin, Dankook University, Korea
      YoonJu Song, The Catholic University of Korea, Korea
      Ta-Chen Su, National Taiwan University, Taiwan
      Gary Sweeney, York University, Canada
      Chin-Hsiao Tseng, National Taiwan University, Taiwan
      Takeshi Usui, Kyoto Medical Center, Japan

    • Manuscript Editors

      Young Ji Choi, InfoLumi, Korea
      Ji Seon Kim, Korean Society for the Study of Obesity, Korea

    • Statistics Editor

      Dae Jung Kim, Ajou University, Korea

    • Ethics Editor

      Hyuk-Sang Kwon, The Catholic University of Korea, Korea

    • English Editors

      Warren Lindeque, University of Johannesburg, South Africa
      Jerry Nairns, Eworld Editing, USA

    • Layout Editor

      Mi Hye Kim, Academya, Korea

    • Website and JATS XML File Producers

      Eun Seok Chae, Inforang Co., Korea

    • Contact Information

      https://www.jomes.org/content/about/contact.html

    • Editorial Office

      Room 1010, Renaissance Tower Bldg., 14, Mallijae-ro, Mapo-gu, Seoul 04195, Korea
      Tel: +82-2-364-0886, Fax: +82-2-364-0883
      E-mail: kosso@kosso.or.kr, Journal E-mail: journal@jomes.org
      Office Homepage: http://www.kosso.or.kr, Homepage: https://www.jomes.org

  • 7. Copyright and Licensing
    • https://www.jomes.org/content/policy/copyright.html
    • 1) Copyright: The copyright of manuscripts that have been accepted for publication is transferred to the Korean Society for the Study of Obesity, and the authors of the article should sign the copyright transfer form. Copyright forms should be sent to the JOMES Editorial Office via fax (+82-2-364-0883), scanned and uploaded to the submission site, or sent via e-mail to journal@jomes.org. The Korean Society for the Study of Obesity also follows the Creative Commons Attribution Non-commercial License as an open-access journal.
    • 2) Licensing information: This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 8. Author fees
    There are no author submission fees or other publication-related fees, since all costs for the publication process are supported by the publisher.
  • 9. Process for identification of and handling allegations of research misconduct
    • 1) Step to prevent research misconduct: When JOMES faces suspected cases of research and publication misconduct, such as duplicate publication, plagiarism, fraudulent or fabricated data, changes in authorship, undisclosed conflicts of interest, and ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, or a complaint against the editors, the resolution process will be as is presented in a flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). All discussion and decisions on the suspected cases are overseen by the JOMES Editorial Board.
    • 2) COPE’s guideline: All processes of handling research and publication misconduct shall follow the applicable Committee of Publication Ethics (COPE) flowchart (https://publicationethics.org/resources/flowcharts). JOMES requests that all authors comply with research and publication ethics policies.
  • 10. Publication ethics
    • 1) Authorship and contributions: https://www.jomes.org/content/authors/research-and-publication-ethics.html
      Authorship credit should be based on: (1) substantial contributions to the conception and design of the study, acquisition of data, and/or analysis and interpretation of data; (2) participation in drafting of the article or revising it critically for important intellectual content; (3) the provision of final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of it are investigated and resolved appropriately. Every author should meet all four of these conditions.
      The corresponding author takes primary responsibility for communication with the journal during manuscript submission, peer review, and publication and typically ensures that all of the journal’s administrative requirements, such as providing details of authorship, ethics committee approval, clinical trial registration documentation, and gathering conflict of interest forms and statements, are properly completed, although these duties may be delegated to one or more coauthors. The corresponding author should be available throughout the submission and peer review process to respond to editorial queries in a timely way and should be available after publication to respond to critiques of the work and cooperate with any requests from the journal for data or additional information should questions arise after publication. Authors are responsible for the whole content of each article.
      After initial submission of a manuscript, any changes in authorship (adding author(s), deleting author(s), or rearranging the order of author(s)) must be explained in a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. JOMES does not correct authorship after acceptance for publication unless a mistake has been made by the editorial staff.
    • 2) Complaints and appeal: How does the journal handle complaints and appeals? The policy of the journal is primarily aimed at protecting the authors, reviewers, editors, and publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics (COPE) available from: https://publicationethics.org/appeals.
      Who may complain or make an appeal? Submitters, authors, reviewers, and readers may register complaints and appeals in various cases, such as falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter to the editor. For complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided. Who is responsible to resolve and handle complaints and appeals? The Editor, Editorial Board, or Editorial Office is responsible for them. What may be the consequence of remedy? It depends on the type or degree of misconduct. The consequence of resolution will follow the guidelines of the Committee of Publication Ethics (COPE).
    • 3) Conflicts of interest: https://www.jomes.org/content/authors/research-and-publication-ethics.html
      A conflict of interest exists when a person’s interpretation of data or presentation of information could be influenced by a personal or financial relationship with other people or organizations. Authors must disclose any financial competing interests. Authors should also reveal any nonfinancial competing interests that may cause them embarrassment were they to become public after publication of the manuscript. Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles.
    • 4) Data sharing and reproducibility
      • Open data policy
        For clarification on result accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository, for example, the Harvard Dataverse (https://dataverse.harvard.edu/dataverse/), after acceptance of the manuscript. Therefore, the submission of raw data or analysis data is mandatory. If the data is already a public one, its URL site or sources could be disclosed. If the data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data, authors should contact the editorial office.
      • Clinical data sharing policy
        This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018, manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement, as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial’s registration. The ICMJE’s policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration, this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All authors of research articles that employ interventional clinical trials must submit a data sharing plan (examples 1 to 4 in Table 1). Based on the degree of the data sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.
    • Table 1. Examples of data sharing statements that fulfill these ICMJE requirements*
      Element Element1 Element2 Element3 Element4
      Will individual participant data be available (including data dictionaries)? Yes Yes Yes Yes
      What data in particular will be shared? All individual participant data collected during the trial, after deidentification Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) Not available
      What other documents will be available? Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code Study protocol, statistical analysis plan, analytic code Study protocol Not available
      When will data be available (start and end dates)? Immediately following publication; no end date Beginning at 3 months and ending at 5 years following the article publication Beginning at 9 months and ending at 36 months following the article publication Not applicable
      With whom? Anyone who wishes to access the data Researchers who provide a methodologically sound proposal Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose Not applicable
      With whom? For what types of analyses? To achieve the aims of the approved proposal. For individual participant data meta-analysis Not applicable
      By what mechanism will the data be made available? Data are available indefinitely at (link to be included). Proposals should be directed to journal@jomes.org. To gain access, data requestors will need to sign a data access agreement. Proposals may be submitted up to 36 months following article publication. After 36 months, the data will be available in our University’s data warehouse but without investigator support other than deposited metadata. Not applicable
      Data are available for 5 years at a third-party website (link to be included). Information regarding submission of proposals and access to data may be found at (link to be provided).
      ICMJE = International Committee of Medical Journal Editors.
      *These examples are meant to illustrate a range of, but not all, data sharing options.
    • 5) Ethical oversight (research ethics, informed consent, IRB, IACUC):
      https://www.jomes.org/content/authors/research-and-publication-ethics.html
      When JOMES faces suspected cases of research and publication misconduct, such as duplicate publication, plagiarism, fraudulent or fabricated data, changes in authorship, undisclosed conflicts of interest, and ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, or a complaint against the editors, the resolution process will be as is presented in a flowchart provided by the Committee on Publication Ethics (COPE) (http://publicationethics.org/resources/flowcharts). All discussion and decisions on the suspected cases are overseen by the JOMES Editorial Board. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.

      Clinical research should be conducted in accordance with the World Medical Association’s Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects). Clinical studies that do not meet the Helsinki Declaration will not be considered for publication.
      For clinical studies with human subjects, there should be a certificate, agreement, or approval by the Institutional Review Board (IRB) of the author’s affiliated institution. In the process of submitting the manuscript, the IRB number should be listed. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct. If a study has been granted an exemption from requiring ethics approval, this should be also be detailed in the manuscript (including the reasons for the exemption, and the name of the ethics committee that granted the exemption). For humans, identifiable information, such as patients’ names, initials, hospital numbers, dates of birth, or other protected health care information, should not be disclosed. Copies of written informed consent forms should be kept for studies on human subjects. This information should be specified in the Methods section of the manuscript. For animal subjects, authors must state that their care was in accordance with national laws and institutional regulations. The ethical treatment of all experimental animals must be approved by an animal ethics review committee and conform to the guidelines provided by the Institutional Animal Care and Use Committee (IACUC).
    • 6) Sex and gender consideration: https://www.jomes.org/content/authors/instructions-to-authors.html
      We encourage our authors to follow the ‘Sex and Gender Equity in Research – SAGER – guidelines (https://researchintegrityjournal.biomedcentral.com/articles/10.1186/s41073-016-0007-6) and to include sex and gender considerations where relevant. Authors should use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Article titles and/or abstracts should indicate clearly what sex(es) the study applies to. Authors should also describe in the background, whether sex and/or gender differences may be expected; report how sex and/or gender were accounted for in the design of the study; provide disaggregated data by sex and/or gender, where appropriate; and discuss respective results. If the study was done in only one sex, we highly recommend authors describe the reasons for the study in a single sex, except in obvious cases (e.g., prostate cancer). If a sex and/or gender analysis was not conducted, the rationale should be given in the Discussion. We suggest that our authors consult the full guidelines before submission.
    • 7) Intellectual property: https://www.jomes.org/content/policy/copyright.html
      All published papers become the permanent property of the Korean Society for the Study of Obesity. Copyrights of all published materials are owned by the Korean Society for the Study of Obesity.
    • 8) Post-publication discussions: The journal’s options for post-publication discussions and corrections: The post-publication discussion is available through a letter to the editor. If any readers have a concern on any articles published, they can submit a letter to the editor regarding the articles. If any error or mistake is found in the article, it can be corrected through errata, corrigenda, or retraction.
  • 11. Publishing schedule
    https://www.jomes.org/content/authors/instructions-to-authors.html#body00
    The journal is published quarterly on March 30, June 30, September 30, and December 30.
  • 12. Access
    https://www.jomes.org/content/policy/open_access.html
    This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 13. Archiving
    It is accessible without barrier from PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/journals/3611/), Korea Citation Index (https://www.kci.go.kr/kciportal/main.kci), or National Library of Korea (http://nl.go.kr) in the event a journal is no longer published.
  • 14. Revenue sources
    https://www.jomes.org/content/authors/instructions-to-authors.html#body05
    The revenue sources of the journal are the support from the publisher (the Korean Society for the Study of Obesity) and Korean government and advertising rates.
  • 15. Advertising
    https://www.jomes.org/content/policy/advertising-policies.html
    The Journal of Obesity & Metabolic Syndrome does not accept any commercial product advertisements until policy changes otherwise.
  • 16. Direct marketing
    Journal propagation is carried out through the journal’s website and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal’s aims and scope.

jomes

September, 2024
Vol.33 No.3

Current Issue
Archives

Mostly popular keywords